Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0412 EUR
−7.14 M EUR
3.96 M EUR
188.51 M
About SOLASIA PHARMA K K
Sector
Headquarters
Tokyo
Founded
2006
Website
ISIN
JP3436500007
FIGI
BBG00GCLYXH6
Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. It provides patients access to western oncology and hematology therapies by developing products licensed from western pharmaceutical and biotechnology companies. The company was founded by Bard Geesaman, John McDonald, and Koji Shinozaki in December 2006 and is headquartered in Tokyo, Japan.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Solasia Pharma K.K. stocks are traded under the ticker 9SO.
We've gathered analysts' opinions on Solasia Pharma K.K. future price: according to them, 9SO price has a max estimate of 0.33 EUR and a min estimate of 0.33 EUR. Watch 9SO chart and read a more detailed Solasia Pharma K.K. stock forecast: see what analysts think of Solasia Pharma K.K. and suggest that you do with its stocks.
Yes, you can track Solasia Pharma K.K. financials in yearly and quarterly reports right on TradingView.
Solasia Pharma K.K. is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
9SO net income for the last quarter is −1.62 M EUR, while the quarter before that showed −1.74 M EUR of net income which accounts for 6.63% change. Track more Solasia Pharma K.K. financial stats to get the full picture.
No, 9SO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 29, 2024, the company has 24.00 employees. See our rating of the largest employees — is Solasia Pharma K.K. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Solasia Pharma K.K. EBITDA is −6.01 M EUR, and current EBITDA margin is −103.57%. See more stats in Solasia Pharma K.K. financial statements.
Like other stocks, 9SO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Solasia Pharma K.K. stock right from TradingView charts — choose your broker and connect to your account.